Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Eli Lilly and CompanyNYSE: LLY

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $7.1B rose 25.3% year over year, behind the +93.6% change in trailing-twelve-month net income. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at +49.0% a year.

Context

  • Net income amounted to 31.7% of revenue in FY2025, up 8.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 18 analysts of $31.7B (+53.6%) for the fiscal year ending Dec 2026, a slowdown from the +94.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$7.1B-4.1% QoQ
Last fiscal yearDec 2025
$20.64B+94.9% YoY
LTMJun 2026
$26.71B+93.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.3%-8.6%-34.0 pp
1 year+94.9%+53.6%-41.3 pp
3-year CAGR+49.0%+35.6%-13.4 pp
5-year CAGR+26.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
20.64B USD
Year-over-year change
+94.9%
4-year CAGR
+38.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +93.6% is the highest of 10, against a peer median of -6.4%.
  • Net income amounts to 33.5% of revenue for LLY, versus a peer median of 16.2%.
LLY Competitors
Net Income for LLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
SNYSanofiLTM Jun 2026€3.96B EUR-46.8%-11.2%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding LLY) —-6.4%+7.9%16.2%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.58B6.24B5.24B10.59B20.64B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
Deferred Income Tax(802.3M)(2.19B)(2.34B)(2.68B)(1.71B)
Stock-Based Compensation342.8M371.1M628.5M645.6M626M
Change in Working Capital(1.01B)(800K)(3.06B)(5.39B)(8.09B)
Accounts Receivables(1.28B)(299.6M)(2.45B)(2.16B)(7B)
Inventory(235.9M)(599.7M)(1.43B)(2.51B)(4.67B)
Accounts Payables(1.01B)1.33B4.27B2.61B10.19B
Other Working Capital1.52B(433.2M)(3.45B)(3.33B)(6.61B)
Other Non-Cash Items1.71B1.63B2.24B3.88B3.35B
Operating Cash Flow7.37B7.59B4.24B8.82B16.81B
Capital Expenditures(1.98B)(2.99B)(7.39B)(5.06B)(7.84B)
Acquisitions (Net)(747.4M)(327.2M)(1.04B)(947.7M)(661M)
Purchases of Investments(1.01B)(707.6M)(829M)(775.8M)(645M)
Sales of Investments847.4M463.6M700.3M522.5M964M
Other Investing Activities(644.3M)(1.34B)(2.53B)303.1M(2.79B)
Investing Cash Flow(2.87B)(3.76B)(7.15B)(9.3B)(10.97B)
Debt Repayment501.4M(62M)8.65B8.9B8.05B
Common Stock Issued00000
Common Stock Repurchased(1.25B)(1.5B)(750M)(2.5B)(4.11B)
Dividends Paid(3.09B)(3.54B)(4.07B)(4.68B)(5.38B)
Other Financing Activities(295.9M)(308.9M)(335M)(490.6M)(772M)
Financing Cash Flow(4.13B)(5.41B)3.5B1.23B(2.21B)
Effect of Forex Changes(205.7M)(167.6M)168.6M(296.7M)372M
Net Change in Cash161.4M(1.75B)751.6M449.8M4B
Free Cash Flow5.39B4.6B(3.15B)3.76B8.97B

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.